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ABSTRACT
Richter transformation (RT), or Richter syndrome, is defined as the transformation of chronic lymphocytic leukemia (CLL) 
to an aggressive B-cell lymphoma. The vast majority, up to 99%, transform into diffuse large B-cell lymphoma (DLBCL), 
with a small subset (<1%) becoming classical Hodgkin lymphoma. Approximately half of RT cases progress through 
a pathway involving dysregulation of C-MYC. High-grade B-cell lymphoma (HGBL) is a recent diagnostic category of 
aggressive B-cell lymphomas set forth in the updated 2017 WHO Classification of Hematopoietic and Lymphoid Tissues. 
HGBL with MYC and BCL2 and/or BCL6 rearrangements, formerly “double-hit” and “triple-hit” lymphomas, comprise 
the majority of HGBL cases. Patients with HGBL have a worse prognosis than those with diffuse large B-cell lymphoma. 
We present a case of RT with rearrangements of MYC and BCL6. To our knowledge, there are no reported cases of RT 
with a “double-hit” lymphoma genotype. 
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CASE REPORT
A 59-year-old man with a 20-year history of 
CLL presented with progressive shortness of breath, 
weight loss, and a rapidly enlarging supraclavicular 
lymph node. Prior therapies included fludarabine, 
rituximab, bendamustine, and ibrutinib. Though 
the CLL was never genetically characterized by 
FISH studies, there was a normal karyotype 3 years 
previously. At presentation, he had a mild microcytic 
anemia (HGB 11.4 g/dL; reference range [RR], 
13.8-17.3 g/dL; MCV 79 fL; RR, 81-95 fL), normal white 
blood cell count (WBC 5,800/mL; RR, 4,000-10,400/mL), 
normal absolute lymphocyte count (ALC 2,090/mL; 
RR, 1,090-3,300/mL), and thrombocytopenia (PLT 
107,000/mL; RR, 141,000-320,000/mL). LDH was 
elevated at 1,850 U/L (RR, 313-618 U/L). Imaging 
showed a large mediastinal mass with compression of 
the left atrium and pulmonary arteries. An excisional 
biopsy of the supraclavicular lymph node showed 
effacement of the normal nodal architecture by sheets 
of intermediate to large atypical lymphocytes with 
irregular nuclear contours and prominent nucleoli 
(Figure 1A). Numerous mitotic figures were present. 
The proliferation index, assessed by KI-67 (MIB-1), was 
increased at 60-70% (Figure 1B).
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Flow cytometry of the lymph node detected a 
lambda-restricted clonal CD5-positive B-cell population 
also positive for CD20(dim) and CD23(dim), and 
negative for CD10 and FMC7 (Figure 2).
This immunophenotype was similar to those seen 
in the patient’s multiple previous specimens, including 
lymph nodes, bone marrow, and peripheral blood over 
the prior 20 years. In the current study, a significant 
component of large cells was seen by light scatter 
criteria.
Cytogenetic studies revealed an abnormal 
karyotype with a translocation between the long 
Figure 1. A – Photomicrograph of the supraclavicular lymph node showing sheets of intermediate-sized cells 
with prominent mitoses (H&E, 40X); B – Ki67 (MIB1) immunohistochemical stain, showing an estimated 60-70% 
proliferation rate (40X).
Figure 2. Flow cytometry of the lymph node, showing a CD19+ CD5+ CD10- lambda-restricted B-cell population. 
CD45 was aberrantly decreased. (SS: Side scatter; PE: Phycoerythrin; PC7: Phycoerythrin cyanin 7; PC5: Phycoerythrin 
cyanin 5; ECD: Electron coupled dye; B1-4, G1-4, F1-4: Plot quadrants).
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arms of chromosomes 8 and 18, additional material 
on the long arm of chromosome 9, and loss of the Y 
chromosome in 8 cells. A normal male karyotype was 
identified in 2 cells. There was an insufficient number 
of dividing cells for a 20-cell study. Fluorescence 
in situ hybridization (FISH) revealed a MYC gene 
rearrangement in 70-80% of cells and a BCL6 gene 
rearrangement in 81% (Figure 3). FISH for BCL2 gene 
rearrangement was negative. Clonal immunoglobulin 
gene rearrangements were detected by molecular 
analysis, but were different than the previous CLL 
clone.
The patient was treated with 3 cycles of R-CHOP, 
and after 2 months imaging showed progression of 
disease. He was started on R-ICE and underwent 
stem cell transplantation with successful engraftment. 
The disease continued to progress with involvement 
of the CNS and ultimately the patient developed 
respiratory failure. He was placed on hospice and 
succumbed to his illness, roughly 9 months after the 
initial diagnosis of transformation.
DISCUSSION
HGBL comprises a group of aggressive, mature 
B-cell lymphomas that can be further categorized as 
either “High-grade B-cell lymphoma with MYC and 
BCL2 and/or BCL6 rearrangements” or “High-grade 
B-cell lymphoma, NOS.”1 Most cases belong in the 
former category, and were previously referred to as 
“double-“ or “triple-hit” lymphomas (HGBL-DH). 
Prior to the 2016 revision to the WHO Classification 
of Hematopoietic and Lymphoid Tissues, these 
malignancies were classified as “B-cell lymphoma, 
unclassifiable, with features intermediate between 
diffuse large B-cell lymphoma and Burkitt lymphoma.” 
These lymphomas typically occur in elderly patients 
and present at an advanced stage. About half have 
morphologic features typical of diffuse large B-cell 
lymphoma (DLBCL), while the other half have either 
morphologic features typical of Burkitt lymphoma 
or overlapping features of both. Thus, it is now 
recommended to do cytogenetic or molecular studies 
on all DLBCL, NOS cases to look for abnormalities of 
MYC, BCL2, and BCL6.2
Within HGBL-DH, which by definition have a 
MYC rearrangement, BCL2 rearrangements are much 
more common than BCL6. One study found that out 
of 326 HGBL-DHs, 62% had rearrangements of MYC 
and BCL2, 16% had MYC, BCL2 and BCL6, and 8% 
MYC and BCL6.3 It is thought that HGBL-DH with 
MYC/BCL2 has a poorer prognosis than those with 
MYC/BCL6.4,5
Richter transformation (RT) is the development of 
an aggressive non-Hodgkin lymphoma in the setting 
of underlying chronic lymphocytic leukemia/small 
lymphocytic lymphoma (CLL/SLL). The onset of RT is 
heralded by sudden clinical deterioration, a marked 
increase in lymphadenopathy, splenomegaly, and 
worsening “B” symptoms such as fever, night sweats, 
Figure 3. A – MYC break apart FISH demonstrating rearrangement of the MYC locus (Yellow: Intact MYC signal; 
Red, Green: Broken MYC signal); B – Conventional karyotype (Arrows indicate abnormal chromosomes listed in the 
ISCN nomenclature). 
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and weight loss. Risk factors for the development of RT 
remain poorly defined. However, several clinical features 
have been associated with RT including elevated serum 
lactate dehydrogenase, progressive lymphadenopathy, 
“B” symptoms, monoclonal gammopathy, and 
extranodal involvement.6 Additionally, one study 
suggested lymph nodes >3 cm, absence of del13q14, 
CD38 expression and usage of IGHV4-39 as additional 
risk factors.7 Biopsy of a suspicious transformation site, 
in our case a rapidly enlarging lymph node, is required 
to establish the diagnosis.
Up to 99% of RT cases are those that result in 
diffuse large B-cell lymphoma (DLBCL), with a small 
subset (<1%) becoming classical Hodgkin lymphoma. 
From a molecular standpoint, RT may develop as a 
clone identical to the pre-existing CLL clone, evolve 
from a bi-clonal phenotype, or arise as an independent, 
secondary lymphoma.8 The former two scenarios likely 
represent a complex, multistep process leading to 
the replication of a malignant clone of germinal or 
post-germinal B-cell origin manifesting as aggressive 
lymphoma. The molecular profile of RT-DLBCL is vastly 
different than that of de novo DLBCL.9 One study using 
whole exome sequencing and copy number analysis 
found, on average, CLL acquires approximately 20 new 
genetic lesions during the transformation process 
including mutations of TP53, NOTCH1, INK4a/ARF, 
and CDKN2A/2B.10,11 About 20% of RT cases are not 
clonally related to the original leukemia.12
Historically, RT has been associated with a dismal 
prognosis, with median survival reported between 
five to eight months from the time of diagnosis.11 
The most significant prognostic indicator in RT is clonal 
relation, with cases that are clonally unrelated having 
a better prognosis in general (median survival 5 years 
vs. 8-16 months).9 Amplification and/or overexpression 
of c-MYC is associated with a particularly poor 
prognosis, even in the absence of translocation to 
an immunoglobulin locus such as IgH.13,14 The overall 
response rate to chemotherapeutic regimens has 
been shown to be 39%, with 12% demonstrating a 
complete response.15
There have been differing study outcomes 
regarding the prognostic significance of HGBL-DH 
MYC/BCL6, with studies reporting both better and 
worse clinical outcomes.5,16,17 Nonetheless, patients 
with HGBL are candidates for more aggressive 
chemotherapy regimens given high rates of relapse 
and poor survival following treatment with standard 
R-CHOP (rituximab, cyclophosphamide, doxorubicin, 
vincristine, prednisone).18 Autologous and allogeneic 
hematopoietic stem cell transplants have been explored 
as therapeutic options, showing modest benefit in 
patients with chemosensitive disease.15
In summary, our case represents a Richter 
transformation to high-grade B-cell lymphoma with 
MYC and BCL6 rearrangements. The immunophenotype 
of the aggressive lymphoma was nearly identical to the 
pre-existing CLL; however, molecular studies did not 
identify a clonal relation.
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